Gyre Therapeutics, Inc. Customer Breakdown
Customer relationships and concentrations across all retained periods. Named customers and their revenue are shown when disclosed. Anonymous customers, customer groups and sales channels are labelled separately. Receivable concentration measures unpaid balances, not revenue contribution. A biggest customer by revenue can be identified only from disclosed customer revenue. Missing names and amounts remain missing; identities are not assumed to match between periods.
| Period / as of | Customer / group | Category | Customer revenue | Share of revenue | Share of trade receivables | Basis and limitations |
|---|
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |